Eindhoven, Netherlands, November 3, 2025 — Medical-device CDMO VIVOLTA has signed a long-term agreement for a dedicated production facility at the High Tech Campus Eindhoven in the Netherlands, enabling the company to deploy new cleanrooms and expand its proprietary MediSpin™ electrospinning platform to support high-volume manufacturing of electrospun implants across cardiovascular, orthopaedic, soft tissue and drug-delivery markets.
Science Significance
The expansion reflects the critical role of advanced manufacturing technologies such as automated electrospinning in generating nanofibre-based medical scaffolds and implants that mimic the extracellular matrix and support tissue regeneration. VIVOLTA’s MediSpin platform enables consistent, reproducible, high-throughput production of such devices — addressing a key scientific barrier in translating electrospun devices from lab scale to clinical/commercial scale. The ability to produce ISO Class 7 clean-room products at scale will help realise next-generation implants requiring precise micro-architecture, material science innovation and robust manufacturing for real-world use.
Regulatory Significance
From a regulatory perspective, scaling to a dedicated facility with ISO 13485 certification and ISO Class 7 cleanrooms strengthens the company’s readiness for regulatory-compliant manufacturing for medical devices (Class II/III) and implants. This facility upgrade signals commitment to Good Manufacturing Practice (GMP) – equivalent for devices, traceability, control of environment, and quality systems. For the cGxP audience, the move underscores the increasing regulatory expectation that novel manufacturing technologies (such as electrospinning) must be robustly validated, scaled-up and controlled before clinical or commercial deployment of advanced devices.
Business Significance
Advertisement
Business-wise, VIVOLTA’s scaling move positions it as a full-service CDMO for high-value electrospun implants, enabling it to win larger contracts, support multiple clients’ technology transfer and commercial launches, and capture expanding market demand in regenerative medicine and advanced drug-delivery devices. The dedicated facility reduces bottlenecks, drives margin improvement and enhances competitiveness. In a MedTech ecosystem increasingly outsourcing development and manufacturing, VIVOLTA’s strategy leverages its proprietary platform, facility footprint and CDMO model to deliver growth.
Patients’ Significance
For patients, the implications are significant: implants derived from electrospun nanofibre scaffolds can offer enhanced regeneration, better biocompatibility, faster healing and reduced complications. By scaling manufacturing, VIVOLTA helps ensure that such advanced regenerative devices move beyond niche to broader availability — meaning more patients in cardiovascular, orthopaedics, wound care and other areas could benefit from next-generation implants with improved performance and reliability.
Policy Significance
On the policy front, VIVOLTA’s expansion aligns with national and regional strategies for high-tech manufacturing in healthcare, innovation ecosystems and deep-tech growth. The Dutch location at High Tech Campus Eindhoven signals governmental support for advanced manufacturing in life sciences, and highlights how device-manufacturing infrastructure is increasingly viewed as integral to health-innovation policy. Moreover, as regulatory scrutiny on advanced manufacturing rises, investment in compliant facilities supports policymakers’ goals around device safety, supply-chain resilience and technology sovereignty.
In sum, VIVOLTA’s decision to scale its manufacturing capability via a dedicated facility at High Tech Campus Eindhoven marks a strategic inflection point in the evolution of electrospun medical-device manufacturing. By deploying its MediSpin™ platform in a Class 7 clean‐room environment and positioning as a CDMO partner for clients targeting commercial-scale launches, the company is bridging the gap between innovative materials research and market-ready implants. For the cGxP community this story is highly relevant: it underscores how manufacturing scale-up, regulatory compliance, business model adaptation and patient-impact converge in the device-industry value chain. Watch this space for devices built on nanofibre scaffolds arriving at scale.
Source: VIVOLTA press release
